FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157343612> ?p ?o ?g. }

• W3157343612 endingPage "803" @default.
• W3157343612 startingPage "791" @default.
• W3157343612 abstract "ABSTRACTIntroduction: Coronavirus disease 2019 (COVID-19) is still increasing worldwide, and as a result, the number of patients with pulmonary fibrosis secondary to COVID-19 will expand over time. Risk factors, histopathological characterization, pathophysiology, prevalence, and management of post-COVID-19 pulmonary fibrosis are poorly understood, and few studies have addressed these issues.Areas covered:This article reviews the current evidence regarding post-COVID-19 pulmonary fibrosis, with an emphasis on the potential risk factors, histopathology, pathophysiology, functional and tomographic features, and potential therapeutic modalities. A search on the issue was performed in the MEDLINE, Embase, and SciELO databases and the Cochrane library between 1 December 2019, and 25 January 2021. Studies were reviewed and relevant topics were incorporated into this narrative review. Expert opinion: Pulmonary sequelae may occur secondary to COVID-19, which needs to be included as a potential etiology in the current differential diagnosis of pulmonary fibrosis. Therefore, serial clinical, tomographic, and functional screening for pulmonary fibrosis is recommended after COVID-19, mainly in patients with pulmonary involvement in the acute phase of the disease. Further studies are necessary to determine the risk factors, markers, pathophysiology, and appropriate management of post-COVID-19 pulmonary fibrosis.KEYWORDS: Coronaviruscovid-19ct-scaninterstitial lung diseaselung functionpost-covid-19pulmonary fibrosispulmonary sequelae Article highlightsPost-COVID-19 pulmonary fibrosis is defined as the presence of persistent and different fibrotic tomographic changes identified on follow-up, often combined with impairment in pulmonary function tests.The prevalence, pathophysiology, and management of post-COVID-19 pulmonary fibrosis remain poorly understood and need to be thoroughly investigated.Patients with a greater risk for post-COVID-19 pulmonary fibrosis include those who are older, male, and smokers and have comorbidities. Other characteristics during the acute phase that enhance the risk of pulmonary sequelae include the presence of dyspnea, duration of hospitalization and intensive care unit stay, use of high-flow oxygen support, need for mechanical ventilation, severity, and development of ARDS. Additionally, higher levels of C-reactive protein, interleukin-6, lactic dehydrogenase, and D-dimer are associated with a greater risk of such pulmonary lesions.Although the main histopathological patterns identified in post-COVID-19 pulmonary fibrosis have not been completely determined, they are probably associated with an organizing and fibrotic phase of diffuse alveolar damage, non-specific interstitial pneumonitis pattern, and organizing pneumonia.The pathogenesis of post-COVID-19 pulmonary fibrosis is partially known and likely multifactorial. The mechanisms associated with such pulmonary lesions include the linkage with angiotensin-converting enzyme receptor 2, epithelial and endothelial to mesenchymal transition, and cytokine storm, with activation and migration of several inflammatory cells. Excessive production of reactive oxygen species and non-protective mechanical ventilation are other potential triggers for post-COVID-19 pulmonary fibrosis.Patients with post-COVID-19 pulmonary fibrosis may present with dyspnea, dry cough, and oxygen desaturation. Reduced diffusion capacity for carbon monoxide and a restrictive pattern are the most common functional abnormalities that may be found in the long term.Tomographic features identified in pulmonary fibrosis secondary to COVID-19 include the presence of architectural distortion, reticular opacities, traction bronchiolectasis, ground-glass opacities, mosaic attenuation, and honeycombing.Strategies to reduce the severity and progression of post-COVID-19 are unclear. Potential therapeutic modalities include anti-fibrotic drugs, prolonged use of corticosteroids, other anti-inflammatory and immunosuppressive drugs, spironolactone, mesenchymal stem cells, and lung transplant.Future studies are necessary to better understand all issues regarding pulmonary fibrosis secondary to COVID-19.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis paper was not funded." @default.
• W3157343612 created "2021-05-10" @default.
• W3157343612 creator A5012044205 @default.
• W3157343612 creator A5020373882 @default.
• W3157343612 creator A5022880534 @default.
• W3157343612 creator A5033302705 @default.
• W3157343612 creator A5040944118 @default.
• W3157343612 creator A5050278072 @default.
• W3157343612 creator A5051844044 @default.
• W3157343612 creator A5060178357 @default.
• W3157343612 date "2021-04-27" @default.
• W3157343612 modified "2023-10-14" @default.
• W3157343612 title "Pulmonary fibrosis secondary to COVID-19: a narrative review" @default.
• W3157343612 cites W1590693684 @default.
• W3157343612 cites W1967986697 @default.
• W3157343612 cites W1971054351 @default.
• W3157343612 cites W1980321651 @default.
• W3157343612 cites W2037466316 @default.
• W3157343612 cites W2064164967 @default.
• W3157343612 cites W2117717444 @default.
• W3157343612 cites W2138871107 @default.
• W3157343612 cites W2154153313 @default.
• W3157343612 cites W2168666423 @default.
• W3157343612 cites W2587955248 @default.
• W3157343612 cites W2697742139 @default.
• W3157343612 cites W2789806998 @default.
• W3157343612 cites W2889431466 @default.
• W3157343612 cites W2974960379 @default.
• W3157343612 cites W3006390878 @default.
• W3157343612 cites W3006627382 @default.
• W3157343612 cites W3006643024 @default.
• W3157343612 cites W3007497549 @default.
• W3157343612 cites W3012253443 @default.
• W3157343612 cites W3012344554 @default.
• W3157343612 cites W3014360862 @default.
• W3157343612 cites W3014561994 @default.
• W3157343612 cites W3014899810 @default.
• W3157343612 cites W3015269808 @default.
• W3157343612 cites W3015784627 @default.
• W3157343612 cites W3016019925 @default.
• W3157343612 cites W3016075808 @default.
• W3157343612 cites W3016832871 @default.
• W3157343612 cites W3018143982 @default.
• W3157343612 cites W3019906742 @default.
• W3157343612 cites W3020463594 @default.
• W3157343612 cites W3020946865 @default.
• W3157343612 cites W3022950950 @default.
• W3157343612 cites W3023909812 @default.
• W3157343612 cites W3024035983 @default.
• W3157343612 cites W3024053676 @default.
• W3157343612 cites W3026032531 @default.
• W3157343612 cites W3027600926 @default.
• W3157343612 cites W3027794044 @default.
• W3157343612 cites W3031365196 @default.
• W3157343612 cites W3033322338 @default.
• W3157343612 cites W3035079953 @default.
• W3157343612 cites W3035135361 @default.
• W3157343612 cites W3035304779 @default.
• W3157343612 cites W3035947417 @default.
• W3157343612 cites W3036110527 @default.
• W3157343612 cites W3036444295 @default.
• W3157343612 cites W3037268105 @default.
• W3157343612 cites W3037632360 @default.
• W3157343612 cites W3038009121 @default.
• W3157343612 cites W3039084627 @default.
• W3157343612 cites W3039570255 @default.
• W3157343612 cites W3039918544 @default.
• W3157343612 cites W3040493725 @default.
• W3157343612 cites W3042744336 @default.
• W3157343612 cites W3043808075 @default.
• W3157343612 cites W3045774637 @default.
• W3157343612 cites W3046330125 @default.
• W3157343612 cites W3048402201 @default.
• W3157343612 cites W3070884292 @default.
• W3157343612 cites W3078290162 @default.
• W3157343612 cites W3080114020 @default.
• W3157343612 cites W3080549988 @default.
• W3157343612 cites W3081384154 @default.
• W3157343612 cites W3081449227 @default.
• W3157343612 cites W3085958090 @default.
• W3157343612 cites W3086562523 @default.
• W3157343612 cites W3087172040 @default.
• W3157343612 cites W3087385130 @default.
• W3157343612 cites W3088153469 @default.
• W3157343612 cites W3090490930 @default.
• W3157343612 cites W3093604087 @default.
• W3157343612 cites W3094124685 @default.
• W3157343612 cites W3094460695 @default.
• W3157343612 cites W3094560858 @default.
• W3157343612 cites W3097201842 @default.
• W3157343612 cites W3097369918 @default.
• W3157343612 cites W3097457001 @default.
• W3157343612 cites W3102574388 @default.
• W3157343612 cites W3108431527 @default.
• W3157343612 cites W3109926113 @default.
• W3157343612 cites W3110514822 @default.
• W3157343612 cites W3110614147 @default.
• W3157343612 cites W3110844195 @default.

• next